Medivir Raises SEK 45 Million in Directed Share Issue to Carl Bennet AB

An update from Medivir AB ( (SE:MVIR) ) is now available.

Medivir AB, a Swedish drug developer focused on serious diseases with limited treatment options, builds its pipeline through a mix of in-house research and external partnerships. The company targets areas of high unmet medical need and is listed on Nasdaq Stockholm’s Small Cap list under the ticker MVIR.

Medivir has completed a directed share issue of 90 million ordinary shares to Carl Bennet AB at a subscription price of SEK 0.50 per share. The transaction raises SEK 45 million before issue costs, strengthening the company’s financial position and potentially supporting continued investment in its drug development programs.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish pharmaceutical company that develops innovative drugs targeting diseases with significant unmet medical needs. The company concentrates on indications where existing treatment options are limited or absent, aiming to deliver substantial patient benefits. Its business model relies heavily on collaborations and partnerships, with drug development carried out both internally and with external partners. Medivir’s shares, traded under the ticker MVIR, are listed on the Nasdaq Stockholm Small Cap market.

Average Trading Volume: 1,694,958

Technical Sentiment Signal: Sell

Current Market Cap: SEK251.2M

For an in-depth examination of MVIR stock, go to TipRanks’ Overview page.